Uruguay genomics for a 3.5M population market where INIA covers cattle genomics, MSP covers public health, and Illumina/BGI serve the private consumer market
Years-long decline before final shutdown · Fatal mistake: Uruguay genomics: MSP (Ministry of Public Health) national genomics program covered public health. INIA (agricultural research) had genomic tools for cattle breeding (Uruguay's primary export). Private genomics services: Illumina and BGI (China) had direct-to-consumer in Spanish via LAB-level services. 3.5M population = maximum 50K genomic test addressable market at any price. No viable commercial genomics market at Uruguay scale.
Evaluating only GenomicsUY’s profile at its peak — without knowing the outcome — the model ranked Regulation as the #1 likely cause. Documented cause: Market too small.
Key Events Timeline
FOUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
GenomicsUY built genomics in Uruguay. INIA (cattle), MSP (public health), Illumina/BGI (consumer) covered primary segments. 3.5M population. ~50K annual test TAM.
Lesson
“Uruguay genomics must serve as the regional Latin American genomics hub — Mercosur has 280M+ people and Uruguay's GDPR-compliant data protection and English-language research capability positions it as a regional precision medicine R&D base.”
Failure anatomy
Collapse type
Slow Death
🐌 LOW
Hype cycle
None
Moat type
Technology
Fatal mistake
Uruguay genomics: MSP (Ministry of Public Health) national genomics program covered public health. INIA (agricultural research) had genomic tools for cattle breeding (Uruguay's primary export). Private genomics services: Illumina and BGI (China) had direct-to-consumer in Spanish via LAB-level services. 3.5M population = maximum 50K genomic test addressable market at any price. No viable commercial genomics market at Uruguay scale.